Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I lapatinib with cisplatin/gemcitabine with or without paclitaxel in advanced or metastatic urothelial cancer
NL-OMON31194Phase 1Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lapatinib in transitional cell carcinoma (TCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Maximum tolerated dose of lapatinib. Started Oct 2007; status: active, not recruiting.
02
Drugs
lapatinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON31194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31194.